Mandate

Vinge has advised Industrifonden and Investinor in connection with a sale of shares in Calliditas

Vinge has advised Industrifonden and Investinor in connection with a sale of in total approximately 2,300,000 shares in Calliditas Therapeutics AB (publ) to two investors for a total value of approximately USD 17,000,000.

Calliditas is listed on Nasdaq Stockholm and focuses on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialization efforts.

Vinge’s team consisted of Dain Hård Nevonen, Sofie Bjärtun, Nils Fredrik Dehlin and Hampus Olsson.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025